Background Lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a and hydroxychloroquine
efficacy for COVID-19 have been evaluated, but detailed evaluation is lacking. Objective …

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of
which can produce disease in humans of all ages and can affect both pulmonary and …

… Marina Tadolini, Luigi Ruffo Codecasa, José-María García-García, François-Xavier Blanc,
Sergey Borisov, Jan-Willem Alffenaar,Claire Andréjak, Pierre Bachez, Pierre-Alexandre Bart …

Aims The role of renin‐angiotensin‐aldosterone system (RAAS) blockers on the course of
coronavirus disease 2019 (COVID‐19) is debated. We assessed the association between …

A significant knowledge gap exists concerning the geographical distribution of nontuberculous
mycobacteria (NTM) isolation worldwide. To provide a snapshot of NTM species …

Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

慢性和背景atory disease and inhaled corticosteroid (ICS) therapy for chronic
obstructive pulmonary disease (COPD) increase the risk of pneumonia. Few data are …

Rationale: Few population-based data are available regarding nontuberculous mycobacteria
(NTM) pulmonary disease epidemiology and prognosis. Objectives: To examine NTM …

Improving treatment outcome reporting in NTM disease: NTM-NET (@ ntmnet) consensus
statement on treatment outcome definitionshttp://ow. ly/c6IC30iwLM4

Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental,
acid-fast-staining bacterial species, some of which may cause disease in humans. Chronic …